Immune Response News and Research

RSS

FDA expands emergency use authorization for Pfizer-BioNTech COVID-19 Vaccine

Today, the U.S. Food and Drug Administration expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 through 15 years of age.

10 May 2021

Study discovers harmful inflammatory protein in patients with symptomatic tuberculosis

A pioneering study by UCL scientists has discovered the presence of a harmful inflammatory protein in patients with symptomatic tuberculosis (TB).

10 May 2021

Blocking fat-busting enzyme with a drug compromises cardiac repair during acute heart failure

Blocking the fat-busting enzyme lipoxygenase with a synthetic inhibitor throws the immune system's innate inflammatory response out of whack, compromising cardiac repair during acute heart failure, USF Health researchers found.

10 May 2021

New vaccine shows potential to protect from a variety of coronavirus infections

A potential new vaccine developed by members of the Duke Human Vaccine Institute has proven effective in protecting monkeys and mice from a variety of coronavirus infections -- including SARS-CoV-2 as well as the original SARS-CoV-1 and related bat coronaviruses that could potentially cause the next pandemic.

10 May 2021

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers in The Netherlands have warned that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces complex reprogramming of innate immune responses that should be considered in the development and use of mRNA-based vaccines.

10 May 2021

Researchers identify first biomarker to predict severity of COVID-19

Severe cases of COVID-19 can now be detected at an early stage. Researchers at the University of Zurich have identified the first biomarker that can reliably predict which patients will develop severe symptoms.

10 May 2021

Scientists produce a universal flu vaccine using nanoparticles to induce long-lasting immunity

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID)’s Vaccine Research Center (VRC) and the University of Washington School of Medicine’s Institute for Protein Design (IPD) developed a universal flu vaccine candidate using small particles (nanoparticles), which can induce a long-lasting immune response.

10 May 2021

Unique infectious profile explains why it is so hard to treat COVID-19

A comprehensive review into what we know about COVID-19 and the way it functions suggests the virus has a unique infectious profile, which explains why it can be so hard to treat and why some people experience so-called "long-COVID", struggling with significant health issues months after infection.

7 May 2021

New research lays the groundwork for an effective salmonella vaccine

With the COVID-19 vaccines on many people's minds, some may be surprised to learn that we do not yet have vaccines for many common infectious diseases.

7 May 2021

UTMB researchers receive $11.3 million grant to study immunopathogenesis of Ebola

Researchers at the University of Texas Medical Branch at Galveston have been awarded an $11.3 Million, multi-year grant from the National Institute of Allergy and Infectious Diseases to study immunopathogenesis of Ebola, and in particular to determine why cells infected with Ebola develop "immune system paralysis," which inhibits immune response, leads to hyperinflammation, and allows the deadly infection to spread.

7 May 2021

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

An interesting new study describes the emergence of several such variants from a chronically immunosuppressed COVID-19 patient, who remained infected for over 170 days before clearing the virus.

7 May 2021

Imbalance in gut microbiota could play a key role in progression of inflammatory skin disorder

Findings presented at today’s EADV 2021 Spring Symposium suggest that an imbalance in gut microbiota (dysbiosis), could play a significant role in the progression of inflammatory skin disease, Hidradenitis Suppurativa (HS).

7 May 2021

Heart Research UK awards grant for new project investigating long-term effects of COVID-19 on the heart

A project at Newcastle University investigating long-term inflammation of the heart following COVID-19 infection has been awarded a grant of almost £150,000 by national charity Heart Research UK.

7 May 2021

Highly efficient immune response in asymptomatic SARS-CoV-2 patients

Researchers in Singapore have investigated the role of SARS-CoV-2-specific antibodies and T-cells in asymptomatic individuals suffering from COVID-19. They found that, contrary to some initial hypotheses, asymptomatic individuals mount an adaptive immune response on par with symptomatic individuals, demonstrating that T cell response does not appear to be correlated with symptom severity.

7 May 2021

Molecular clues explain why some neurons are more susceptible than others in Alzheimer’s disease

In the brain of a person with Alzheimer's disease, neurons degenerate and die, slowly eliminating memories and cognitive skills. However, not all neurons are impacted equally.

7 May 2021

SARS-CoV-2 infection prolongs viral shedding and lymphocyte loss in patients with cancer

Patients with cancer have a more challenging time with infections while undergoing treatment — placing them as high-risk for severe COVID-19 illness and death. However, how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interacts with cancer therapies remains poorly understood.

7 May 2021

Bubonic plague had long-term impact on human immune genes, indicates study

Scientists examining the remains of 36 bubonic plague victims from a 16th century mass grave in Germany have found the first evidence that evolutionary adaptive processes, driven by the disease, may have conferred immunity on later generations of people from the region.

7 May 2021

Immune Response News and Research

FDA expands emergency use authorization for Pfizer-BioNTech COVID-19 Vaccine

Study discovers harmful inflammatory protein in patients with symptomatic tuberculosis

Blocking fat-busting enzyme with a drug compromises cardiac repair during acute heart failure

New vaccine shows potential to protect from a variety of coronavirus infections

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers identify first biomarker to predict severity of COVID-19

Scientists produce a universal flu vaccine using nanoparticles to induce long-lasting immunity

Unique infectious profile explains why it is so hard to treat COVID-19

New research lays the groundwork for an effective salmonella vaccine

UTMB researchers receive $11.3 million grant to study immunopathogenesis of Ebola

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

Imbalance in gut microbiota could play a key role in progression of inflammatory skin disorder

Heart Research UK awards grant for new project investigating long-term effects of COVID-19 on the heart

Highly efficient immune response in asymptomatic SARS-CoV-2 patients

Molecular clues explain why some neurons are more susceptible than others in Alzheimer’s disease

SARS-CoV-2 infection prolongs viral shedding and lymphocyte loss in patients with cancer

Bubonic plague had long-term impact on human immune genes, indicates study

Large-scale study focuses on COVID-19 antibodies in asymptomatic and symptomatic patients

Study: Novavax Covid-19 vaccine is efficacious against the B.1.351 South African variant

Aberrant immune features in healthy elderly and male subjects with severe COVID-19 may predate infection

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News